Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. Also provided are methods of treating hypertriglyceridemia (200 mg/dL-500 mg/dL) by adjunctive administration of a statin and the pharmaceutical compositions described herein. Further treatment methods include, inter alia, treatments to increase plasma EPA:AA ratios, treatments to decrease ApoCIII levels, and treatments to reduce or prevent resistance to platelet aggregation inhibitors.

Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

Abstract: A method is provided for making aromatic bis(ether phthalic anhydride)s by effecting an imide-anhydride exchange between aromatic bis(ether N-organophthalimide) and phthalic anhydride in the presence of an imide anhydride exchange catalyst and water and extracting the aqueous imide-anhydride exchange reaction mixture with an inert organic solvent. Imide-anhydride exchange product having at least 97 mole percent aromatic bis(ether phthalic anhydride) can be made at substantially reduced temperatures and pressures, by increasing by a factor of at least two, the number of times the imide-anhydride exchange mixture is extracted.

Abstract: A method is provided for making aromatic bis(ether phthalic anhydride), for example, 2,2-bis[4-(3,4-dicarboxyphenoxy)phenyl]propane dianhydride by effecting an exchange reaction between molten aromatic bis(ether-imide) and phthalic anhydride in the presence of water and an imide-anhydride exchange catalyst. An enchanced rate of aromatic bis(ether phthalic anhydride) production has been found to occur, if the molten aromatic bis(ether imide) is contacted with the phthalic anhydride in the form of an aqueous feed mixture of phthalic acid and exchange catalyst and the resulting equilibrated mixture extracted with organic solvent.